Xyratex (XRTX) News Today → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free XRTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesShort InterestSocial MediaStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineXORTX Reprices Warrants Issued in Connection with Previous Private Placementsglobenewswire.com - April 30 at 1:54 PMXORTX Therapeutics Inc. (XRTX.V)ca.finance.yahoo.com - April 26 at 1:44 PMXORTX Announces Publication of Key Research in ADPKDglobenewswire.com - April 22 at 7:00 AMXORTX Welcomes New Member to the Board of Directorsglobenewswire.com - April 8 at 7:30 AMXORTX Therapeutics Inc XRTXmorningstar.com - April 5 at 2:02 PMXORTX Therapeutics Inc. Common Stock (XRTX)nasdaq.com - April 1 at 12:03 AMXORTX Announces New Clinical Advisory Board Memberglobenewswire.com - March 27 at 5:00 AMXORTX: A Year of Milestones and Strategic Advancements as it Readies for a Registration Clinical Trialfinance.yahoo.com - March 19 at 10:23 AMXORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trialglobenewswire.com - March 19 at 5:00 AMXORTX Reprices Warrants Issued in Connection with Previous Private Placementsfinance.yahoo.com - March 11 at 9:23 AMmarketbeat.com - March 7 at 9:51 AMXORTX Finalizes $2.7 Million Prospectus Supplement and Concurrent Private Placement for the Offering of Unitsglobenewswire.com - March 4 at 7:00 AMXORTX Raises $2.5 Million Under Prospectus Supplement and Concurrent Private Placement for the Offering of Unitsfinance.yahoo.com - February 15 at 8:36 AMXORTX Files an Amended and Restated Prospectus Supplement for the Offering of Unitsfinance.yahoo.com - February 2 at 2:05 AMXORTX Announces $2 Million Public Offeringfinance.yahoo.com - January 15 at 7:31 AMXORTX Therapeutics Stock (NASDAQ:XRTX), Analyst Ratings, Price Targets, Predictionsbenzinga.com - January 5 at 5:32 PMXORTX Submits a New Patent for the Treatment of Chronic Kidney Diseasefinance.yahoo.com - January 3 at 8:42 AMXORTX Announces US ATM Offeringfinance.yahoo.com - November 30 at 8:28 AMXORTX Meets Nasdaq Continued Listing Requirementsfinance.yahoo.com - November 29 at 9:21 AMmarketbeat.com - November 14 at 6:03 AMXORTX Clarifies Timing for Share Consolidationfinance.yahoo.com - November 10 at 10:32 AMmarketbeat.com - November 10 at 6:00 AMXORTX Announces Share Consolidationfinance.yahoo.com - November 8 at 8:19 PMXORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2023finance.yahoo.com - November 2 at 7:34 AMXORTX Announces Results of Special Meeting of Shareholdersfinance.yahoo.com - October 27 at 5:48 PMXORTX Announces Date for Rescheduled Special Meeting of Shareholdersfinance.yahoo.com - October 25 at 6:11 PMXORTX Announces Rescheduling of Special Meeting of Shareholdersfinance.yahoo.com - October 25 at 8:10 AMXORTX Calls Special Meeting of Shareholdersfinance.yahoo.com - October 4 at 10:23 AMXORTX Sponsored Study Selected for Presentation at the American Society of Nephrology – Kidney Week 2023finance.yahoo.com - September 28 at 10:19 AMXORTX Joins the Kidney Foundation and Kidney Marchfinance.yahoo.com - September 7 at 11:10 AMXORTX Submits Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Diseasefinance.yahoo.com - August 29 at 8:50 AMA Christmas-Comes-Early Portfoliothestreet.com - August 23 at 5:43 PMXORTX Appoints Chief Financial Officerfinance.yahoo.com - August 4 at 7:24 PMXORTX Announces Results of Annual and Special Meeting of Shareholdersfinance.yahoo.com - June 29 at 10:18 AMXORTX Announces PKD Presentationfinance.yahoo.com - June 6 at 8:15 AMXORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiencyfinance.yahoo.com - May 24 at 9:43 AMXORTX Therapeutics' Xorlo eligible for accelerated approval, confirms FDAmsn.com - May 6 at 8:49 AMFDA Confirms Eligibility of XORLO™ for Accelerated Approvalfinance.yahoo.com - May 4 at 10:26 AMXORTX Announces Receipt of FDA Orphan Drug Designation to Treat Autosomal Dominant Kidney Diseasefinance.yahoo.com - April 21 at 8:18 AMXORTX Announces Type D Meeting with FDA to be held May 1, 2023finance.yahoo.com - March 14 at 10:14 AMXORTX Provides Update on 2022 Achievements and 2023 Planned Milestonesfinance.yahoo.com - February 7 at 9:46 AMXORTX Announces Submission of Orphan Drug Designation Request for XRx-008 Program to Treat Autosomal Dominant Kidney Diseasefinance.yahoo.com - February 1 at 8:26 AMXORTX Files New Provisional Patent to Diagnose and Treat Individuals Most at Risk of Polycystic Kidney Disease Progressionfinance.yahoo.com - January 3 at 8:15 AM5 Heavily-Shorted Stocks Set to Reportthestreet.com - December 27 at 1:47 PMXORTX Announces Completion of Dosing in XRX-OXY-101 Clinical Studyfinance.yahoo.com - December 19 at 7:49 AMXORTX Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease (ADPKD)finance.yahoo.com - December 8 at 8:52 AMXORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Studyfinance.yahoo.com - November 28 at 8:51 AMXRTX XORTX Therapeutics Inc.seekingalpha.com - November 24 at 8:07 PMXORTX Therapeutics Appoints Stacy Evans, M.D., MBA as Chief Business Officerfinance.yahoo.com - November 16 at 5:00 PMXORTX Presents New Proof of Concept Data at American Society of Nephrologybenzinga.com - November 4 at 9:11 PM Get Xyratex News Delivered to You Automatically Sign up to receive the latest news and ratings for XRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. XRTX Media Mentions By Week XRTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XRTX News Sentiment▼0.000.40▲Average Medical News Sentiment XRTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XRTX Articles This Week▼10▲XRTX Articles Average Week Get Xyratex News Delivered to You Automatically Sign up to receive the latest news and ratings for XRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SNPX News ALZN News FWBI News SONN News KZIA News CING News OGEN News PXMD News NEXI News LIPO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XRTX) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyDave Ramsey Shocks Millions With US Dollar LunacyAmerican Hartford Gold GroupTrump is sounding the alarmPreserve GoldBiden’s Sneaky H.R. 5376 Is A Nightmare For Retirement SaversBirch GoldThe best inflation-proof investment DTIAI “wealth window” is closing June 25thParadigm PressThe 2024 crypto bull run has already started — don’t get left behindInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xyratex Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
